Most here,? simply have no idea of the degree of Regulatory, Parliamentary, and NHS Investigative Scrutiny the Phase III Clinical Trial & Subsequent Published data is under right NOW.
And all of you here should applaud this kind of in-depth review, for it is one of the cornerstone due-diligence processes, that ensures that any MHRA decision about a drug or treatment, is respected around the World by other Regulators, who will typically fall inline behind the UK’s decisions.
Market Data 
Markets 
AI
